{"id":"W2150475127","doi":"10.1093/annonc/mdh278","title":"A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Regional Cancer Foundation; BC Cancer Agency","funders":"AstraZeneca Canada","keywords":"Docetaxel; Medicine; Taxane; Neutropenia; Regimen; Internal medicine; Carboplatin; Cancer; Clinical trial; Prostate cancer; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cisplatin; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001110485,0.000171531,0.001490674,0.0001841466,0.00002847031,0.000001388137,0.00009149664,0.000138121,0.00008318037],"category_scores_gemma":[0.0004602373,0.0001363805,0.0000772288,0.0002525827,0.0002447937,0.0001283776,0.00003639402,0.0002334833,1.117378e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000363206,"about_ca_system_score_gemma":0.005407495,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.127584,"about_ca_topic_score_gemma":0.3719148,"domain_scores_codex":[0.9974603,0.0003510698,0.001263992,0.0003082824,0.0003928759,0.0002234452],"domain_scores_gemma":[0.9975927,0.0005493979,0.001093377,0.0001341458,0.0004990957,0.0001312618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.548533,0.08226018,0.218972,0.000307945,0.003145047,0.0001384762,0.002495398,0.0006553466,0.001590439,0.00006641581,0.005010811,0.1368249],"study_design_scores_gemma":[0.6104865,0.11183,0.259139,0.0003346335,0.0005639246,0.000002647962,0.0002977277,0.00000568362,0.0009414429,0.0000935754,0.01609982,0.0002050819],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945095,0.001152536,0.000001402446,0.001432593,0.0005903214,0.001851344,0.0002177351,0.000004156691,0.0002404435],"genre_scores_gemma":[0.9975883,0.00128076,0.00007555133,0.0005952294,0.0001526104,0.0002220407,0.00002949287,0.0000117095,0.000044282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2443308,"threshold_uncertainty_score":0.9592664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1989070396041286,"score_gpt":0.5251946068362316,"score_spread":0.3262875672321031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}